(Q46642643)

23 December 2017

title

alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma (English)

1 reference

23 December 2017

0 references

Chen LT

1

1 reference

23 December 2017

Liu TW

2

1 reference

23 December 2017

Chao Y

3

1 reference

23 December 2017

Shiah HS

4

1 reference

23 December 2017

Chang JY

5

1 reference

23 December 2017

Juang SH

6

1 reference

23 December 2017

Chen SC

7

1 reference

23 December 2017

Chuang TR

8

1 reference

23 December 2017

Chin YH

9

1 reference

23 December 2017

Whang-Peng J

10

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

23 December 2017

Alimentary Pharmacology & Therapeutics

published in

1 reference

23 December 2017

volume

22

1 reference

23 December 2017

issue

3

1 reference

23 December 2017

page(s)

217-226

1 reference

23 December 2017

Diagnosis and follow-up of small hepatocellular carcinoma with selective intraarterial digital subtraction angiography

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Expression of vascular endothelial growth factor in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Low-dose thalidomide treatment for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Salvage therapy for hepatocellular carcinoma with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Thalidomide for advanced hepatocellular carcinoma: is this a real alternative?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Tumor angiogenesis: past, present and the near future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02547.X

10.1111/J.1365-2036.2005.02547.X

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017